epsilon 3. drug indication space. repositioning. The novel approach.
- epsilon 3 assembles experts in translational clinical research, computational biology and business each holding more than 20 years of experience in the respective field.
- Now joined for advancing drug indication space analysis and drug repositioning.
- Our solutions are unique, leveraging on a large data-driven repositioning concept.
- We add value in drug development by exploring a drug’s indication space before entering clinical testing, and by identifying repositioning opportunities of tested or approved drugs.